Proactiveinvestors USA & Canada Antibe Therapeutics Proactiveinvestors USA & Canada Antibe Therapeutics RSS feed en Wed, 22 May 2019 04:03:41 -0400 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[Media files - Antibe Therapeutics is a potential game changer in pain management ]]> Wed, 17 Apr 2019 16:09:00 -0400 <![CDATA[News - Antibe grants Kinght commercial rights for drug candidates ]]> Antibe Therapeutics (CVE:ATE), a commercial-stage healthcare company, signed an exclusive long-term license and distribution agreement with Knight Therapeutics (TSE:GUD), a Canadian specialty pharmaceutical company, for Antibe’s anti-inflammatory and pain drugs, ATB-346, ATB-352 and ATB-340, as well as the rights to other, future Antibe prescription drugs.

Antibe granted Westmount, Quebec-based Knight the exclusive commercial rights for Antibe’s drug candidates and other future prescription drugs in Canada, Israel, Romania, Russia and sub-Saharan Africa, the Toronto-based company said in a statement on Monday.

Antibe is entitled to royalties on annual sales, along with the potential for $10mln in payments for sales-based milestones.

Antibe said it considers this a favourable royalty scenario given its competitive anticipated cost-of-goods structure.

The global market for non-steroidal anti-inflammatory and pain drugs is more than US$12 billion annually, despite serious side effects for the currently marketed drugs, especially when taken over the long-term.

Antibe’s drug candidates are novel and patent-protected, and are designed to be safer versions of drugs currently on the market.

Also on Monday, Antibe announced a second closing of the non-brokered private placement of convertible debentures announced October 16, bringing the total proceeds to $2.6mln.

The first tranche of the financing was led by the Bloom Burton Healthcare Lending Trust and the major investor in the second tranche is Knight.

The funds will be used to further the development of Antibe’s novel anti-inflammatory drug pipeline and to fuel the growth of Antibe following its acquisition of an 85% interest in Citagenix Inc.

The Debentures will mature on October 15, 2018, bear interest at a rate of 10% per year, and are convertible at the holder’s option into common shares of Antibe at a price of $0.22 per share.

“The world needs safer anti-inflammatory drugs, and we are pleased to have secured Antibe’s innovative portfolio for our territories, Knight CEO Jonathan Ross Goodman said in the statement.

Mon, 16 Nov 2015 09:32:00 -0500
<![CDATA[News - Antibe Therapeutics plunges 80% on suspending lead drug’s phase I clinical trial ]]> Antibe Therapeutics (CVE:ATE) crumbled 80 percent after the Canadian pharmaceutical company said it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial.

Shares were down C$0.075 at 10 a.m. in Toronto, leaving the company with a market value of C$3.3 million.

Safety concerns centered on the finding of significant liver enzyme elevations in one subject in the highest dose cohort and additional liver enzyme elevations were observed in other subjects in the higher dose cohorts, the Toronto-based company said in a statement today.

Antibe said it is concerned that, when assessed together, these liver enzyme elevations are indicative of potential hepatotoxicity.

ATB-346 targets the need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation.

“Our primary concern is with the health of the subjects,”  Dan Legault, Antibe’s chief executive officer, said in the statement.

“We are very disappointed by these unexpected findings and will fully assess our options moving forward.”

Pre-clinical studies on ATB-346 provided no indication of potential hepatotoxicity, the company said.

Antibe said it continues to collect and assess data and will report back to the scientific community and the market with further details on its data review and corporate strategy as appropriate.

ATB-352, the second drug in Antibe’s pipeline, targets the need for a safer analgesic for severe acute pain.

Fri, 16 Jan 2015 10:22:00 -0500
<![CDATA[News - Antibe Therapeutics seeks to fill market void with “ground-breaking” class of painkiller drugs ]]> With a successful public offering this summer, Antibes Therapeutics (CVE:ATE) continues development of a drug that promises to impact quality of life for hundreds of millions of people, “and many every day for the rest of their lives,” explains company president and CEO Dan Legault.

The new drug fits into the category known as non-steroidal anti-inflammatory drugs or NSAIDs.  With a global market of over $12 billion annually, NSAIDs constitute the largest drug category, and although a very common prescription and over-the-counter medication, the current form of these drugs has serious side effects.

Since NSAID introduction four decades ago, their side effects have been well known, including stomach and intestinal ulcers and bleeding, among other gastrointestinal issues.   

“It’s the number one cause of adverse drug reactions in western-world hospitals and it’s also a very large opportunity for anyone who can solve the problem,” says Legault.  

Enter Antibe.

The company boasts an impressive management team. “Chief scientific officer Dr. John Wallace is one of the most respected NSAIDs scientists in the world”, says Legault. Much of this is due to his work establishing how NSAIDs caused gastrointestinal damage.

Dr. Wallace leveraged Nobel-prize-winning work carried out in the ‘80s and ‘90s on the subject of gaseous mediators — chemical substances produced in the human body to regulate a range of fundamental cellular processes. One of these gaseous mediators is hydrogen sulphide — a pivotal element in how the Antibe non-inflammatory NSAID differs from all its predecessors.

“Dr. Wallace 12 years ago discovered that hydrogen sulfide played a critical role in mediating or managing inflammation in the human body. He also had the idea of taking a molecule that releases hydrogen sulfide and molecularly attaching that molecule to another molecule, namely an off-patent drug, and thereby increasing its effectiveness and reducing its toxicity. 

“When we created a hydrogen sulfide-releasing version of several NSAIDs, they were very, very promising.”

For medical conditions characterized by inflammation, pain or vascular dysfunction, the company says its methodologies can produce improved versions of a number of existing drugs. The company’s lead drug, ATB-346, addresses the need for more effective pain relief for sufferers of osteoarthritis, the most common form of arthritis and a degenerative disease that affects the cartilage that caps the end of bones.

Legault says Antibe’s years of rigorous work have generated the most extensive research ever published in this field, as well as revealing the drug’s excellent results on animals.  “Stage for stage, our drug proved to be the safest NSAID out there and with that, we moved forward down the regulatory pathway.”

Legault describes this regulatory pathway as “significant and risky”, not to mention beset with difficulty in gathering venture funding — the usual source of financing for early stage development of ‘chronic drugs’ (that is, drugs that can be taken for a long time) in the Western world. 

“Venture funding for chronic drugs has decreased  significantly in recent years,” says Legault. “In 2007, this would have been easy — no more. While the venture community in North America saw our science and data were superb, many felt the regulatory pathway was too risky, given the financing environment.”

With that, China and Brazil stepped up as early markets for the drug and the fit seems ideal.

“Our drug is needed in the developing world. Their middle classes are growing at a huge rate.  There are hundreds of millions of people who need our drug in these markets,” Legault points out. 

Under the deal hammered out with a large regional Chinese pharma, funding will be provided to Antibe to further move the drug through its trials in exchange for later licensing. A similar deal is at the letter of intent stage with a South American firm.

With that funding in place, the direct costs are covered for the two phases of clinical trials required for the West, and the three phases required for China.

The additional money required to fund the program management was raised through a public offering in June that culminated in the company “hitting [its] maximum raise” says Legault — no mean feat for the first pharmaceutical company to go public since the 2008 crash.

With that, the company is well positioned to push through to the end of the pre-clinical trials, which are proceeding on schedule.

“Amassing our resources was like reaching base camp at Everest.  Now, we’ve started climbing and it’s exciting to see the summit ahead.”

Overseeing the work on Antibe’s board are Dr. Roderick Flower, an academic and a fellow of the Royal Society; Jonathan Goodman, the founder and chair of specialty pharmaceutical company Paladin Labs; and Walt Macnee, recruited by Mastercard Worldwide in 2006 to take the credit card giant public.

While the ex-lawyer and rescue pilot finds himself surrounded by PhDs, Legault says he’s now earned his “PhD in Murphy’s Law”. That’s why he’s built a third team working towards the development of the drug.   “It’s a world-class external review team that serves as a very collegial, but hard-hitting, devil’s advocate. This group will push on our regulatory strategy very hard.”

“Our goal overall is to reduce risk of human error, any flaws in strategy and ultimately let the drug speak for itself. It’s a challenging process, but one that promises big rewards at the end,” Legault says.  “What’s more, if we’re successful, this drug could ease the misery of 100 million people — that’s inspiring.”

Wed, 09 Oct 2013 10:37:00 -0400
<![CDATA[News - Antibe Therapeutics completes second tranche of IPO ]]> Antibe Therapeutics (CVE:ATE) said it has raised a total of $2.7 million after completing the second tranche of its initial public offering. 

When the Toronto-based pharmaceutical company went public in June, it had raised $2.1 million, as well as $155,100 in a private placement. In the second closing, Antibe raised $602,800.

Antibe's lab work focuses on updating existing drugs by linking an off-patent drug to its hydrogen sulfide-releasing molecule for the treatment of inflammation, pain or vascular dysfunction.

Antibe's team includes a Nobel Prize winner, entrepreneurs and senior scientists affiliated with major research institutions worldwide.

As of the end of March, the company had $194,301 in cash on hand, a 108% rise from the end of last March. In fiscal 2013, the company reported a loss of $1 million or five cents a share. 

Shares were unchanged on Wednesday at 54 cents a share. 

Wed, 14 Aug 2013 15:08:00 -0400